帕博利珠单抗联合伊匹木单抗对比安慰剂治疗PD-L1≥50%转移性NSCLC的III期KEYNOTE-598研究
KEYNOTE-598是一项随机双盲III期试验,纳入568例未经治疗、PD-L1 TPS≥50%且无EGFR/ALK变异的转移性NSCLC患者,1:1接受伊匹木单抗或安慰剂联合帕博利珠单抗。结果显示联合伊匹木单抗未改善总生存(21.4 vs 21.9个月,HR 1.08)和无进展生存(8.2 vs 8.4个月,HR 1.06),且3-5级不良事件和致死性不良事件发生率更高。研究因无效提前终止,不支持在该人群中以联合方案替代帕博利珠单抗单药。
要点
- 联合伊匹木单抗未改善OS(HR 1.08)或PFS(HR 1.06)。
- 联合组3-5级不良事件发生率62.4%,高于对照组的50.2%。
- 联合组致死性不良事件发生率13.1%,高于对照组的7.5%。
核心结论
- 在PD-L1 TPS≥50%且无EGFR/ALK变异的转移性NSCLC一线治疗中,帕博利珠单抗联合伊匹木单抗未改善疗效且毒性增加。
研究设计与样本
- 随机双盲III期KEYNOTE-598试验(NCT03302234),纳入568例未经治疗的转移性NSCLC患者,PD-L1 TPS≥50%且无EGFR/ALK变异。
- 患者1:1随机接受伊匹木单抗1 mg/kg或安慰剂每6周(最多18剂),所有患者接受帕博利珠单抗200 mg每3周(最多35剂)。
- 主要终点为总生存和无进展生存。
主要发现
- 3-5级不良事件发生率:联合组62.4% vs 对照组50.2%。
- 致死性不良事件发生率:联合组13.1% vs 对照组7.5%。
关键数值与推荐
- 外部数据与安全监查委员会建议因无效提前终止研究,并停用伊匹木单抗和安慰剂。
临床怎么用
- 对于PD-L1 TPS≥50%且无EGFR/ALK变异的转移性NSCLC一线治疗,不应以帕博利珠单抗联合伊匹木单抗替代帕博利珠单抗单药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pembrolizumab monotherapy is standard first-line therapy for metastatic non-small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 50% without actionable driver mutations. It is not known whether adding ipilimumab to pembrolizumab improves efficacy over pembrolizumab alone in this population. METHODS: In the randomized, double-blind, phase III KEYNOTE-598 trial (ClinicalTrials.gov identifier: NCT03302234), eligible patients with previously untreated metastatic NSCLC with PD-L1 TPS ≥ 50% and no sensitizing EGFR or ALK aberrations were randomly allocated 1:1 to ipilimumab 1 mg/kg or placebo every 6 weeks for up to 18 doses; all participants received pembrolizumab 200 mg every 3 weeks for up to 35 doses. Primary end points were overall survival and progression-free survival. RESULTS: Of the 568 participants, 284 were randomly allocated to each group. Median overall survival was 21.4 months for pembrolizumab-ipilimumab versus 21.9 months for pembrolizumab-placebo (hazard ratio, 1.08; 95% CI, 0.85 to 1.37; P = .74). Median progression-free survival was 8.2 months for pembrolizumab-ipilimumab versus 8.4 months for pembrolizumab-placebo (hazard ratio, 1.06; 95% CI, 0.86 to 1.30; P = .72). Grade 3-5 adverse events occurred in 62.4% of pembrolizumab-ipilimumab recipients versus 50.2% of pembrolizumab-placebo recipients and led to death in 13.1% versus 7.5%. The external data and safety monitoring committee recommended that the study be stopped for futility and that participants discontinue ipilimumab and placebo. CONCLUSION: Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than pembrolizumab monotherapy as first-line treatment for metastatic NSCLC with PD-L1 TPS ≥ 50% and no targetable EGFR or ALK aberrations. These data do not support use of pembrolizumab-ipilimumab in place of pembrolizumab monotherapy in this population.
引用
- Boyer M, Şendur MAN, Rodríguez-Abreu D, et al. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. J Clin Oncol. 2021. PMID: 33513313. doi:10.1200/JCO.20.03579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。